News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kedem Pharmaceuticals (KDMP.OB) Completes North American Dosage Forms for X-Excite



1/6/2012 2:38:09 PM

PHOENIX, AZ--(Marketwire - January 10, 2012) - Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that has completed all the dosages production of X-Excite, the Company's lead therapeutic drug for erectile dysfunction.

Three dosages of the drug were manufactured with the final dosage forms (10, 25 and 50 mg) and appropriate labeling. The Company awaits the data from the labs on the dosages stability and disintegration studies. These studies are underway currently and once all completed, the Company can move towards the North American Clinical Trials.

"We are very pleased with the completion of dosage form and labeling, a requirement of regulatory bodies for the eventual drug approval," said Dr. Hassan Salari, Chairman and CEO of Kedem Pharmaceuticals Inc.

About X-Excite

X-Excite is a sublingual formulation of sildenafil citrate developed by Kedem Pharmaceuticals Inc. for sexual enhancement. Currently sildenafil citrate is marketed by Pfizer under the registered name Viagra®, as an oral application for erectile dysfunction.

About Kedem Pharmaceuticals Inc.

KDMP.ob is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.

Forward-looking Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to un foreseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.


For further information, contact:
Kedem Investor Relations
1 866 465-6551
info@kedempharmaceuticals.com

Or

Mrs. Kelly Black
Premier Media Services
1 480 649 8224
kblack@premiermediaservice.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES